Novo Integrated Sciences (NVOS)
OTHER OTC:NVOS
Want to see NVOS full AI Analyst Report?
Top Page
Novo Integrated Sciences
(OTC:NVOS)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.00
▼(-100.00% Downside)
Action:N/A
Date:07/18/25
The overall stock score of 45 reflects significant concerns in financial performance, with persistent losses and weak cash flows posing the greatest risks. High volatility indicated by beta and a negative P/E ratio further weigh on the score, with no positive catalysts from technicals or valuation to offset these challenges.
Positive Factors
Revenue Growth
Consistent revenue growth indicates expanding market reach and product adoption, which can support long-term business sustainability.
Negative Factors
Negative Profit Margins
Negative profit margins indicate operational inefficiencies and high costs, which can hinder profitability and long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates expanding market reach and product adoption, which can support long-term business sustainability.
Read all positive factors
Novo Integrated Sciences (NVOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$177.57K
Dividend YieldN/A
Average Volume (3M)46.26K
Price to Earnings (P/E)―
Beta (1Y)2.78
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,730,247
10 Day Avg. Volume11,807
30 Day Avg. Volume46,255
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.38
Price to Sales (P/S)0.43
P/FCF Ratio-2.48
Enterprise Value/Market Cap23.99
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda-0.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Novo Integrated Sciences Business Overview & Revenue Model
Company Description
Novo Integrated Sciences, Inc. (NVOS) delivers a diverse array of primary healthcare services and related products through its two primary operational segments: Healthcare Services and Product Manufacturing and Development. The company's extensive...
How the Company Makes Money
Novo Integrated Sciences generates revenue through several key streams, including the sale of its proprietary health and wellness products, licensing agreements for its technology and products, and partnerships with healthcare providers and distri...
Novo Integrated Sciences Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
20
Very Negative
| Breakdown | Aug 2024 | Nov 2023 | Feb 2023 | Nov 2021 | Aug 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.29M | 12.57M | 11.74M | 9.31M | 7.86M |
| Gross Profit | 5.74M | 4.95M | 4.80M | 3.82M | 3.06M |
| EBITDA | -10.08M | -5.85M | -22.48M | -2.58M | -2.78M |
| Net Income | -16.13M | -13.21M | -32.85M | -4.46M | -4.92M |
Balance Sheet | |||||
| Total Assets | 32.14M | 35.56M | 40.87M | 61.96M | 35.39M |
| Cash, Cash Equivalents and Short-Term Investments | 844.58K | 416.32K | 2.18M | 8.29M | 2.07M |
| Total Debt | 4.71M | 4.47M | 13.00M | 13.71M | 4.39M |
| Total Liabilities | 17.53M | 11.06M | 18.83M | 18.15M | 5.82M |
| Stockholders Equity | 14.89M | 24.82M | 22.31M | 43.86M | 29.62M |
Cash Flow | |||||
| Free Cash Flow | -2.29M | -2.29M | -6.07M | -1.28M | -453.80K |
| Operating Cash Flow | -2.24M | -2.24M | -5.88M | -1.02M | -441.69K |
| Investing Cash Flow | -49.22K | -49.22K | 163.46K | 3.00M | 657.13K |
| Financing Cash Flow | 763.86K | 763.86K | -427.12K | 4.32M | -271.69K |
Novo Integrated Sciences Risk Analysis
Novo Integrated Sciences disclosed 16 risk factors in its most recent earnings report. Novo Integrated Sciences reported the most risks in the "Ability to Sell" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Novo Integrated Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $98.21M | -0.32 | 184.97% | ― | -0.87% | 10.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $9.67M | -6.20 | -8.75% | ― | -0.62% | -200.79% | |
46 Neutral | $19.71M | -0.03 | ― | ― | 20.26% | 69.68% | |
46 Neutral | $29.25M | -10.76 | 15.82% | 11.14% | -2.56% | -2181.76% | |
45 Neutral | $177.57K | -0.01 | -81.43% | ― | ― | ― | |
40 Underperform | $3.83M | -0.57 | -99.99% | ― | -35.26% | 51.06% |
* Healthcare Sector Average
NVOS
Novo Integrated Sciences
0.02
-0.04
-66.67%
AMS
American Shared Hospital Services
1.42
-0.95
-40.08%
CCM
Concord Medical Services
4.41
-2.21
-33.43%
CCEL
Cryo-Cell International
3.56
-1.53
-30.06%
PIII
P3 Health Partners
12.23
5.55
83.08%
MNDR
Mobile-health Network Solutions Class A
0.67
-5.43
-89.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.